Cargando…

Congenital sacrococcygeal PNET and chemotherapy

We present the case of a congenital localised sacrococcygeal primitive neuroectodermal tumor treated aggressively with surgical resection and modified age-appropriate adjuvant chemotherapy. The conventional combination chemotherapy of vincristine, adriamycin, cyclophosphamide, ifosfamide and etoposi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawkes, Colin Patrick, Betts, David R., O’Brien, John, O’Sullivan, Maureen J., Capra, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523479/
https://www.ncbi.nlm.nih.gov/pubmed/23248428
http://dx.doi.org/10.4103/0971-5851.103151
_version_ 1782253211019640832
author Hawkes, Colin Patrick
Betts, David R.
O’Brien, John
O’Sullivan, Maureen J.
Capra, Michael
author_facet Hawkes, Colin Patrick
Betts, David R.
O’Brien, John
O’Sullivan, Maureen J.
Capra, Michael
author_sort Hawkes, Colin Patrick
collection PubMed
description We present the case of a congenital localised sacrococcygeal primitive neuroectodermal tumor treated aggressively with surgical resection and modified age-appropriate adjuvant chemotherapy. The conventional combination chemotherapy of vincristine, adriamycin, cyclophosphamide, ifosfamide and etoposide was modified to a regimen including vincristine, adriamicin, cyclophosphamide and actinomycin in order to minimise the predicted toxicity in this age group. Adjuvant “induction” chemotherapy commenced at 4 weeks of age and consisted of four cycles of vincristine, adriamycin and cyclophosphamide at 50%, 75%, 75% and 100% of recommended doses (vincristine 0.05 mg/kg, adriamycin 0.83 mg/kg daily × 2, cyclophosphamide 40 mg/kg) at 3-weekly intervals. This was followed by four cycles of “maintenance” chemotherapy with vincristine (0.025 mg/kg), actinomycin (0.025 mg/kg) and cyclophosphamide (36 mg/kg) at full recommended doses. Cardioxane at a dose of 16.6 mg/kg was infused immediately prior to the adriamycin. Our patient is thriving at 19 months out from end of treatment.
format Online
Article
Text
id pubmed-3523479
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-35234792012-12-17 Congenital sacrococcygeal PNET and chemotherapy Hawkes, Colin Patrick Betts, David R. O’Brien, John O’Sullivan, Maureen J. Capra, Michael Indian J Med Paediatr Oncol Case Report We present the case of a congenital localised sacrococcygeal primitive neuroectodermal tumor treated aggressively with surgical resection and modified age-appropriate adjuvant chemotherapy. The conventional combination chemotherapy of vincristine, adriamycin, cyclophosphamide, ifosfamide and etoposide was modified to a regimen including vincristine, adriamicin, cyclophosphamide and actinomycin in order to minimise the predicted toxicity in this age group. Adjuvant “induction” chemotherapy commenced at 4 weeks of age and consisted of four cycles of vincristine, adriamycin and cyclophosphamide at 50%, 75%, 75% and 100% of recommended doses (vincristine 0.05 mg/kg, adriamycin 0.83 mg/kg daily × 2, cyclophosphamide 40 mg/kg) at 3-weekly intervals. This was followed by four cycles of “maintenance” chemotherapy with vincristine (0.025 mg/kg), actinomycin (0.025 mg/kg) and cyclophosphamide (36 mg/kg) at full recommended doses. Cardioxane at a dose of 16.6 mg/kg was infused immediately prior to the adriamycin. Our patient is thriving at 19 months out from end of treatment. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3523479/ /pubmed/23248428 http://dx.doi.org/10.4103/0971-5851.103151 Text en Copyright: © Indian Journal of Medical and Paediatric Oncology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Hawkes, Colin Patrick
Betts, David R.
O’Brien, John
O’Sullivan, Maureen J.
Capra, Michael
Congenital sacrococcygeal PNET and chemotherapy
title Congenital sacrococcygeal PNET and chemotherapy
title_full Congenital sacrococcygeal PNET and chemotherapy
title_fullStr Congenital sacrococcygeal PNET and chemotherapy
title_full_unstemmed Congenital sacrococcygeal PNET and chemotherapy
title_short Congenital sacrococcygeal PNET and chemotherapy
title_sort congenital sacrococcygeal pnet and chemotherapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523479/
https://www.ncbi.nlm.nih.gov/pubmed/23248428
http://dx.doi.org/10.4103/0971-5851.103151
work_keys_str_mv AT hawkescolinpatrick congenitalsacrococcygealpnetandchemotherapy
AT bettsdavidr congenitalsacrococcygealpnetandchemotherapy
AT obrienjohn congenitalsacrococcygealpnetandchemotherapy
AT osullivanmaureenj congenitalsacrococcygealpnetandchemotherapy
AT capramichael congenitalsacrococcygealpnetandchemotherapy